СОГЛАСОВАННАЯ ЭКСПЕРТНАЯ ПОЗИЦИЯ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ФУЛЬМИНАНТНОГО МИОКАРДИТА В УСЛОВИЯХ ПАНДЕМИИ COVID-19
Оригинальная статья
Дата публикации: сентября 17, 2020
Ключевые слова
COVID-19
вирус SARS-CoV-2
цитокиновый шторм
вирус SARS-CoV-2
цитокиновый шторм
Как цитировать
[1]
О. Ш. Ойноткинова, СОГЛАСОВАННАЯ ЭКСПЕРТНАЯ ПОЗИЦИЯ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ФУЛЬМИНАНТНОГО МИОКАРДИТА В УСЛОВИЯХ ПАНДЕМИИ COVID-19, КМКВ, вып. 3, сс. 5-18, сен. 2020.
Аннотация
Представлено российское экспертное консенсусное заявление по диагностике и лечению фульминантного миокардита(ФМ), подготовленное Национальным обществом по изучению проблем липидологии и ассоциированных метаболических заболеваний, Межрегиональным обществом внутренней, спортивной и профилактической терапии, основанное на клинических рекомендациях Российского кардиологического общества, данных китайского клинического исследования (NCT03268642),экспертных рекомендациях по клиническому лечению повреждений миокарда, связанных с новой коронавирусной инфекцией, Национального гериатрического клинического медицинского исследовательского центра, отделения сердечнососудистых заболеваний китайского гериатрического общества, отделения кардиологии Пекинской Медицинской Ассоциации. Обсуждаются вопросы патогенеза, диагностики и лечения повреждения миокарда и ФМ у больных, инфицированных SARS-Co-V2 в условиях пандемии COVID-19. Представлены клинические особенности и диагностические критерии ФМ, комплексная схема лечения повреждения миокарда и ФМ, направленная на поддержание жизнедеятельности в условиях COVID-19. Предложенный протокол ведения пациентов с повреждением миокарда, инфицированных SARS-Co-V2, адаптирован с учетом клинического опыта работы китайских экспертов с таким контингентом больных, а протокол по антикоагулянтной и антитромбоцитарной терапии предложен Медицинским центром МГУ.Литература
1. Caforio A. L. P. et al. Current state of knowledge onaetiology, diagnosis, management, and therapy of myocarditis: apposition statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases // European heart journal. – 2013. – V. 34. – №. 33. – P. 2636-2648.
2. Caforio A. L. P. et al. Myocarditis: a clinical overview //Current Cardiology Reports. – 2017. – V. 19. – №. 7. – С. 63.
3. Fung G. et al. Myocarditis // Circulation Research. – 2016.– V. 118. – №. 3. – P. 496-514.
4. Lazaros G., Oikonomou E., Tousoulis D. Established and novel treatment options in acute myocarditis, with or without heart failure // Expert Review of Cardiovascular Therapy. – 2017. – V.15. – №. 1. – P. 25-34.
5. Luyt C. E., Hékimian G., Ginsberg F. What’s new in myocarditis? // Intensive care medicine. – 2016. – V. 42. – №.6. – P. 1055-1057.
6. Pollack A. et al. Viral myocarditis—diagnosis, treatment options, and current controversies // Nature Reviews Cardiology. –2015. – V. 12. – №. 11. – P. 670.
7.Ginsberg F., Parrillo J. E. Fulminant myocarditis // Criticalcare clinics. – 2013. – V. 29. – №. 3. – P. 465-483.
8. Gupta S. et al. Fulminant myocarditis // Nature clinical practice cardiovascular medicine. – 2008. – V. 5. – №. 11. – P.693-706.
9. Maisch B., Ruppert V., Pankuweit S. Management of fulminant myocarditis: a diagnosis in search of its etiology but with therapeutic options // Current heart failure reports. – 2014. – V.11. – №. 2. – P. 166-177.
10. McCarthy R. E. et al. Long-term outcome of fulminant myocarditis as compared with acute (no fulminant) myocarditis //New England Journal of Medicine. – 2000. – V. 342. – №. 10. – P.690-695.
11. Huang C. et al. Clinical features of patients infected with2019 novel coronavirus in Wuhan, China // The lancet. – 2020. –V. 395. – №. 10223. – P. 497-506.
12. Wang D. et al. Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis // Science China Life Sciences. – 2019. – V.62. – №. 2. – P. 187-202.
13. Felker G. M. et al. Echocardiographic findings in fulminantand acute myocarditis // Journal of the American College of Cardiology. – 2000. – V. 36. – №. 1. – P. 227-232.
14. Sun D. et al. Value of SOFA, APACHE IV and SAPS II scoring systems in predicting short-term mortality in patients with acute myocarditis // Oncotarget. – 2017. – V. 8. – №. 38. – P.63073.
15. Chen J. et al. Trimetazidine prevents macrophage mediated septic myocardial dysfunction via activation of the histonedeacetylase sirtuin 1 // British journal of pharmacology. – 2016. –V. 173. – №. 3. – P. 545-561.
16. Kühl U. et al. Interferon-Beta improves survival in enterovirus-associated cardiomyopathy // Journal of the American College of Cardio logy. – 2012. – V. 60. – №. 14. – P. 1295-1296.
17. Bjelakovic B., Vukomanovic V., Jovic M. Fulminant myocarditis in children successfully treated with high dose of methylprednisolone// Ind J Pediatr. – 2016. – V. 83. – P. 268-269.
18. Goland S. et al. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature // Canadian Journal of Cardiology. – 2008.– V. 24. – №. 7. – P. 571-574.
19. Drucker N. A. et al. Gamma-globulin treatment of acute myocarditis in the pediatric population // Circulation. – 1994. – V.89. – №. 1. – P. 252-257.
20. Kishimoto C. et al. Therapy with immunoglobulin in patientswith acute myocarditis and cardiomyopathy: analysis of leukocyte balance // Heart and vessels. – 2014. – V. 29. – №. 3. – P. 336-342.
21. Yu D. Q. et al. Intravenous immunoglobulin in the therapy of adult acute fulminant myocarditis: A retrospective study //Experimental and therapeutic medicine. – 2014. – V. 7. – №. 1.– P. 97-102.22. Isogai T. et al. Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: propensity score analyses // Journal of cardiac failure. – 2015. – V. 21. – №. 5.– P. 391-397.
23. Ihdayhid A. R., Chopra S., Rankin J. Intra-aortic balloon pump: indications, efficacy, guidelines and future directions //Current opinion in cardiology. – 2014. – V. 29. – №. 4. – P. 285-292.
24. Okai I. et al. Transbrachial intra-aortic balloon pumping for a patient with fulminant myocarditis // Heart and vessels. –2012. – V. 27. – №. 6. – P. 639-642.
25. Yang G. et al. Experiences of treating fulminant myocarditis with multiple organ failure. // Journal of American College of Cardiology. – 2017. – T. 70. - № 16. – P.122.
26. Diddle J. W. et al. Extracorporeal membrane oxygenation for the support of adults with acute myocarditis // Critical caremedicine. – 2015. – V. 43. – №. 5. – P. 1016-1025.
27. Hsu K. H. et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center’s experience // European journal of cardio-thoracic surgery. – 2011.– V. 40. – №. 3. – P. 682-688.
28. Lorusso R. et al. Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients: a5-year multi-institutional experience // The Annals of thoracic surgery. – 2016. – V. 101. – №. 3. – P. 919-926.29. Nakamura T. et al. Prognosis of patients with fulminant myocarditis managed by peripheral venoarterial extracorporeal membranous oxygenation support: a retrospective single-center study // Journal of intensive care. – 2015. – V. 3. – №. 1. – P. 5.
30. Pozzi M. et al. Veno-arterial extracorporeal membrane oxygenation for cardiogenic shock due to myocarditis in adult patients// Journal of thoracic disease. – 2016. – V. 8. – №. 7. – P. E495.
31. Bulut D. et al. Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy// Clinical research in cardiology. – 2010. – V. 99. – №. 10. – P.633-638.
32. Jensen L. D., Marchant D. J. Emerging pharmacologic targets and treatments for myocarditis // Pharmacology &Therapeutics. – 2016. – V. 161. – P. 40-51. doi: 10.1016/j.pharmthera.2016.03.006.
33. Nishiura H., Linton N. M., Akhmetzhanov A. R. Initial Cluster of Novel Coronavirus (2019-nCoV) Infections in Wuhan, China Is Consistent with Substantial Human-to-Human Transmission // J. Clin. Med. – 2020. – V. 9. – P. 488.
34. Клинические рекомендации по диагностике и лечению миокардитов, утвержденные Минздравом России 2019г. [Clinical recommendations for the diagnosis and treatment of myocarditis approved by the Ministry of health of the Russian Federation in 2019. In Russian].
35. Wang D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China // Jama. – 2020. – V. 323. – №. 11. – P. 1061-1069.
36. China National Health Commission et al. Diagnosis and treatment of pneumonitis caused by new coronavirus (trial version 6)// Beijing: China National Health Commission. – 2020.
37. Wang D. et al. Chinese Expert Consensus Statement on Clinical Diagnosis and Treatment of Fulminant Myocarditis in Adults // Chinese Journal of Cardiology. – 2017. – V. 45. - №9. – P. 742–752.
38. National Geriatrics Center, National Geriatrics Clinical Medicine Research Center, Cardiovascular Disease Branch of Chinese Geriatrics Society, Department of Cardiology, Beijing Medical Association. Expert recommendations for clinical management of myocardial injury associated with new coronavirus infection // Chinese Circulation Journal. - 2020.
39. Landoni G. et al. Cardiac protection with phosphocreatine: a meta-analysis // Interactive Cardiovascular and Thoracic Surgery. – 2016. – V. 23. – №. 4. – P. 637-646.
40. Mingxing F. et al. Phosphocreatine in cardiac surgery patients: a meta-analysis of randomized controlled trials // Journalof cardiothoracic and vascular anesthesia. – 2018. – V. 32. – №.2. – P. 762-770.
41. Li Jun, Li Hongzhu, Li Ping, et.al. Effect of creatinephosphate on children coxsackie virus myocarditis // Journal ofApplied Clinical Pediatrics. – 2010. – V. 6. – P. 424-426.
42. Niu L. et al. 124 cases of clinical analysis of children with viral myocarditis // Eur Rev Med Pharmacol Sci. – 2015. – V. 19.– №. 15. – P. 2856-2859.
43. Tао J. et al. Therapeutic effect of creatine phosphate on serious viral myocarditis with heart failure [J] // Medical Journal ofWest China. – 2007. – V. 4.
44. Gao Dengfeng. Xi’an Jiaotong University Second Affiliated Hospital Anti-epidemic National Medical Team: High-dose vitamin C-based Jiaotong Program [J]. 2020.
45. Мареев В. Ю. и др. Клинические рекомендации ОССН-РКО-РНМОV. Сердечная недостаточность: хроническая(ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение // Кардиология. – 2018. – Т. 58. – №.6S. – С. 8-158. [Mareev V.Yu. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment// Kardiologiia. – 2018. – V. 58. – №. 6S. – P. 8-158. In Russian]. doi:10.18087/cardio.2475.
46. Методические рекомендации. Анестезиолого-реанимационное обеспечение пациентов с новой коронавирусной инфекцией COVID-19, Москва, 2020 г. [Guidelines. Anesthetic and resuscitation support for patients with a new coronavirus infection COVID-19, Moscow, 2020. In Russian].
47. Libby P., Simon D. I. Inflammation and thrombosis: the clot thickens // Circulation. – 2001. – V. 103. – №. 13. – P. 1718.
48. Bansal M. Cardiovascular disease and COVID-19 //Diabetes & Metabolic Syndrome. – 2020. – V. 14. – №. 3. – P.247-250. doi:10.1016/j.dsx.2020.03.013.
49. Driggin E. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19pandemic // Journal of the American College of Cardiology. – 2020.– V. 75. – №. 18. – P. 2352-2371.doi: 10.1016/j.jacc.2020.03.031.
50. Xiong T. Y. et al. Coronaviruses and the cardiovascularsystem: acute and long-term implications // European Heart Journal. – 2020. – V. 41. – №. 19. – P. 1798-1800. doi: 10.1093/eurheartj/ehaa231.
2. Caforio A. L. P. et al. Myocarditis: a clinical overview //Current Cardiology Reports. – 2017. – V. 19. – №. 7. – С. 63.
3. Fung G. et al. Myocarditis // Circulation Research. – 2016.– V. 118. – №. 3. – P. 496-514.
4. Lazaros G., Oikonomou E., Tousoulis D. Established and novel treatment options in acute myocarditis, with or without heart failure // Expert Review of Cardiovascular Therapy. – 2017. – V.15. – №. 1. – P. 25-34.
5. Luyt C. E., Hékimian G., Ginsberg F. What’s new in myocarditis? // Intensive care medicine. – 2016. – V. 42. – №.6. – P. 1055-1057.
6. Pollack A. et al. Viral myocarditis—diagnosis, treatment options, and current controversies // Nature Reviews Cardiology. –2015. – V. 12. – №. 11. – P. 670.
7.Ginsberg F., Parrillo J. E. Fulminant myocarditis // Criticalcare clinics. – 2013. – V. 29. – №. 3. – P. 465-483.
8. Gupta S. et al. Fulminant myocarditis // Nature clinical practice cardiovascular medicine. – 2008. – V. 5. – №. 11. – P.693-706.
9. Maisch B., Ruppert V., Pankuweit S. Management of fulminant myocarditis: a diagnosis in search of its etiology but with therapeutic options // Current heart failure reports. – 2014. – V.11. – №. 2. – P. 166-177.
10. McCarthy R. E. et al. Long-term outcome of fulminant myocarditis as compared with acute (no fulminant) myocarditis //New England Journal of Medicine. – 2000. – V. 342. – №. 10. – P.690-695.
11. Huang C. et al. Clinical features of patients infected with2019 novel coronavirus in Wuhan, China // The lancet. – 2020. –V. 395. – №. 10223. – P. 497-506.
12. Wang D. et al. Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis // Science China Life Sciences. – 2019. – V.62. – №. 2. – P. 187-202.
13. Felker G. M. et al. Echocardiographic findings in fulminantand acute myocarditis // Journal of the American College of Cardiology. – 2000. – V. 36. – №. 1. – P. 227-232.
14. Sun D. et al. Value of SOFA, APACHE IV and SAPS II scoring systems in predicting short-term mortality in patients with acute myocarditis // Oncotarget. – 2017. – V. 8. – №. 38. – P.63073.
15. Chen J. et al. Trimetazidine prevents macrophage mediated septic myocardial dysfunction via activation of the histonedeacetylase sirtuin 1 // British journal of pharmacology. – 2016. –V. 173. – №. 3. – P. 545-561.
16. Kühl U. et al. Interferon-Beta improves survival in enterovirus-associated cardiomyopathy // Journal of the American College of Cardio logy. – 2012. – V. 60. – №. 14. – P. 1295-1296.
17. Bjelakovic B., Vukomanovic V., Jovic M. Fulminant myocarditis in children successfully treated with high dose of methylprednisolone// Ind J Pediatr. – 2016. – V. 83. – P. 268-269.
18. Goland S. et al. Intravenous immunoglobulin treatment for acute fulminant inflammatory cardiomyopathy: series of six patients and review of literature // Canadian Journal of Cardiology. – 2008.– V. 24. – №. 7. – P. 571-574.
19. Drucker N. A. et al. Gamma-globulin treatment of acute myocarditis in the pediatric population // Circulation. – 1994. – V.89. – №. 1. – P. 252-257.
20. Kishimoto C. et al. Therapy with immunoglobulin in patientswith acute myocarditis and cardiomyopathy: analysis of leukocyte balance // Heart and vessels. – 2014. – V. 29. – №. 3. – P. 336-342.
21. Yu D. Q. et al. Intravenous immunoglobulin in the therapy of adult acute fulminant myocarditis: A retrospective study //Experimental and therapeutic medicine. – 2014. – V. 7. – №. 1.– P. 97-102.22. Isogai T. et al. Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: propensity score analyses // Journal of cardiac failure. – 2015. – V. 21. – №. 5.– P. 391-397.
23. Ihdayhid A. R., Chopra S., Rankin J. Intra-aortic balloon pump: indications, efficacy, guidelines and future directions //Current opinion in cardiology. – 2014. – V. 29. – №. 4. – P. 285-292.
24. Okai I. et al. Transbrachial intra-aortic balloon pumping for a patient with fulminant myocarditis // Heart and vessels. –2012. – V. 27. – №. 6. – P. 639-642.
25. Yang G. et al. Experiences of treating fulminant myocarditis with multiple organ failure. // Journal of American College of Cardiology. – 2017. – T. 70. - № 16. – P.122.
26. Diddle J. W. et al. Extracorporeal membrane oxygenation for the support of adults with acute myocarditis // Critical caremedicine. – 2015. – V. 43. – №. 5. – P. 1016-1025.
27. Hsu K. H. et al. Extracorporeal membranous oxygenation support for acute fulminant myocarditis: analysis of a single center’s experience // European journal of cardio-thoracic surgery. – 2011.– V. 40. – №. 3. – P. 682-688.
28. Lorusso R. et al. Venoarterial extracorporeal membrane oxygenation for acute fulminant myocarditis in adult patients: a5-year multi-institutional experience // The Annals of thoracic surgery. – 2016. – V. 101. – №. 3. – P. 919-926.29. Nakamura T. et al. Prognosis of patients with fulminant myocarditis managed by peripheral venoarterial extracorporeal membranous oxygenation support: a retrospective single-center study // Journal of intensive care. – 2015. – V. 3. – №. 1. – P. 5.
30. Pozzi M. et al. Veno-arterial extracorporeal membrane oxygenation for cardiogenic shock due to myocarditis in adult patients// Journal of thoracic disease. – 2016. – V. 8. – №. 7. – P. E495.
31. Bulut D. et al. Effect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy// Clinical research in cardiology. – 2010. – V. 99. – №. 10. – P.633-638.
32. Jensen L. D., Marchant D. J. Emerging pharmacologic targets and treatments for myocarditis // Pharmacology &Therapeutics. – 2016. – V. 161. – P. 40-51. doi: 10.1016/j.pharmthera.2016.03.006.
33. Nishiura H., Linton N. M., Akhmetzhanov A. R. Initial Cluster of Novel Coronavirus (2019-nCoV) Infections in Wuhan, China Is Consistent with Substantial Human-to-Human Transmission // J. Clin. Med. – 2020. – V. 9. – P. 488.
34. Клинические рекомендации по диагностике и лечению миокардитов, утвержденные Минздравом России 2019г. [Clinical recommendations for the diagnosis and treatment of myocarditis approved by the Ministry of health of the Russian Federation in 2019. In Russian].
35. Wang D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China // Jama. – 2020. – V. 323. – №. 11. – P. 1061-1069.
36. China National Health Commission et al. Diagnosis and treatment of pneumonitis caused by new coronavirus (trial version 6)// Beijing: China National Health Commission. – 2020.
37. Wang D. et al. Chinese Expert Consensus Statement on Clinical Diagnosis and Treatment of Fulminant Myocarditis in Adults // Chinese Journal of Cardiology. – 2017. – V. 45. - №9. – P. 742–752.
38. National Geriatrics Center, National Geriatrics Clinical Medicine Research Center, Cardiovascular Disease Branch of Chinese Geriatrics Society, Department of Cardiology, Beijing Medical Association. Expert recommendations for clinical management of myocardial injury associated with new coronavirus infection // Chinese Circulation Journal. - 2020.
39. Landoni G. et al. Cardiac protection with phosphocreatine: a meta-analysis // Interactive Cardiovascular and Thoracic Surgery. – 2016. – V. 23. – №. 4. – P. 637-646.
40. Mingxing F. et al. Phosphocreatine in cardiac surgery patients: a meta-analysis of randomized controlled trials // Journalof cardiothoracic and vascular anesthesia. – 2018. – V. 32. – №.2. – P. 762-770.
41. Li Jun, Li Hongzhu, Li Ping, et.al. Effect of creatinephosphate on children coxsackie virus myocarditis // Journal ofApplied Clinical Pediatrics. – 2010. – V. 6. – P. 424-426.
42. Niu L. et al. 124 cases of clinical analysis of children with viral myocarditis // Eur Rev Med Pharmacol Sci. – 2015. – V. 19.– №. 15. – P. 2856-2859.
43. Tао J. et al. Therapeutic effect of creatine phosphate on serious viral myocarditis with heart failure [J] // Medical Journal ofWest China. – 2007. – V. 4.
44. Gao Dengfeng. Xi’an Jiaotong University Second Affiliated Hospital Anti-epidemic National Medical Team: High-dose vitamin C-based Jiaotong Program [J]. 2020.
45. Мареев В. Ю. и др. Клинические рекомендации ОССН-РКО-РНМОV. Сердечная недостаточность: хроническая(ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение // Кардиология. – 2018. – Т. 58. – №.6S. – С. 8-158. [Mareev V.Yu. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment// Kardiologiia. – 2018. – V. 58. – №. 6S. – P. 8-158. In Russian]. doi:10.18087/cardio.2475.
46. Методические рекомендации. Анестезиолого-реанимационное обеспечение пациентов с новой коронавирусной инфекцией COVID-19, Москва, 2020 г. [Guidelines. Anesthetic and resuscitation support for patients with a new coronavirus infection COVID-19, Moscow, 2020. In Russian].
47. Libby P., Simon D. I. Inflammation and thrombosis: the clot thickens // Circulation. – 2001. – V. 103. – №. 13. – P. 1718.
48. Bansal M. Cardiovascular disease and COVID-19 //Diabetes & Metabolic Syndrome. – 2020. – V. 14. – №. 3. – P.247-250. doi:10.1016/j.dsx.2020.03.013.
49. Driggin E. et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19pandemic // Journal of the American College of Cardiology. – 2020.– V. 75. – №. 18. – P. 2352-2371.doi: 10.1016/j.jacc.2020.03.031.
50. Xiong T. Y. et al. Coronaviruses and the cardiovascularsystem: acute and long-term implications // European Heart Journal. – 2020. – V. 41. – №. 19. – P. 1798-1800. doi: 10.1093/eurheartj/ehaa231.